(1/13) Please RT: our first #tweetorial!
Here's a 🧵on our new paper which is also my 1st time being (joint) last author✍️
Congrats to all, especially superstar med student @LuszczakSabina!
#AcademicTwitter @AcademicChatter @OpenAcademics #womeninSTEM
nature.com/articles/s4159…
(2/13) In #prostatecancer cell lines & human tissue, co-targeting #PIM & #PI3K #kinases seems promising!
We reckon ~20% of prostate cancer patients could benefit from this approach in future & these tend to be the sicker patients.
Scroll for #science!
nature.com/articles/s4159…
(3/13) Fig1a:
From publicly available data we see that some patients overexpress either the #PIM pathway, the #PI3K pathway, or both. Each of these targets have inhibitors in development, that could theoretically be of benefit to any of these patient groups when combined 🤞
(4/13) Fig1b+c:
These patients who could hopefully benefit from this co-targeted approach also happen to tend to be sicker (higher Gleason, lower survival) 🏥
(5/13) Fig2:
At the RNA level in 3 #prostatecancer cell lines, inhibition of #PIM/ #PI3K lead to decreased expression of a range of downstream genes, & co-targeted inhibition of both pathways lead to decreased expression of a wider range of #genes, as you might expect!
(6/13) Fig3: At the phospho-protein level, we see similar trends, with the co-targeted approach yielding the most striking inhibition, particularly in the most aggressive cell line (C4-2B) - this was encouraging👍
(7/13) Fig4: All the inhibitors lead to dose-dependent reductions in proliferation in all cell lines, with the lowest IC50s coming from the triple kinase inhibitor #AUM302, in the nM range.
Nice drug! Thanks: @AumBiosciences @InflectionBio @CNIOStopCancer #drugdevelopment
(8/13) Fig5: In human #exvivo cultures, we see the same story, with improved inhibition of proliferation & induction of apoptosis when we co-target both pathways. Note the conc differences!
This fig is a taster of the work to be expanded on in my new lab #comingsoon #heaveylab
(9/13) limitations: the ex vivo work is only in a few patients, we may have been lucky & we can’t assume this would work so well for everyone – probably only around a fifth will respond like this. Or maybe more… only one way to find out!
(10/13) Next steps:@ProstateUK @MovemberUK have funded us to expand this cohort substantially & carry out detailed molecular work. Much of the collection & culture has already happened, with thanks to @UCLpathology @uclhrobotics
prostatecanceruk.org/research/resea… #fellowship #womeninSTEM
(11/13) Acknowledgements [part 1] for the work above!
Big thanks to the authors including these tweeters -follow them! @LuszczakSabina @HayleyWhitaker @kathygately1 @b3nsimp @hayleyjeanpye @linamacarmona @aimhaider @acesridhar @greglshaw @TheWhitakerlab
nature.com/articles/s4159…
(12/13) Acknowledgements [part 2] for the work above!
Many thanks for supporting this work:
Collab:@InflectionBio @AumBiosciences
Journal:@SciReports @SpringerNature
Funders:@ProstateUK @MovemberUK
Hosts:@UCLDivofSurgery @UCL @UCLpathology @uclhrobotics
nature.com/articles/s4159…
(13/13) Now we party? 🥳🙌🎊🎏
(⬇️please imagine them 2m apart 😷)
#publication #AcademicChatter #AcademicTwitter #WomeninSTEM #scicomm
nature.com/articles/s4159…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.